Physician profile
Mark Yazid
NPI 1134532005
$4,815.04
in general payments reported to CMS, 2019-2025
20 companies · $592 in 2025
The $592 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $563 · 2021: $1,151 · 2022: $627 · 2023: $1,409 · 2024: $355 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165 · Travel and Lodging: $1,015 · Long Term Medical Supply Or Device Loan: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.68 |
| Travel and Lodging | $1,015.18 |
| Long Term Medical Supply Or Device Loan | $176.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,224.89 | 2020-2022 | |
| Arthrex, INC. | $1,174.18 | 2023 | |
| Abbvie INC. | $332.86 | 2023-2025 | Revolve |
| Integra Lifesciences Corporation | $279.67 | 2024-2025 | Integra, Amnioexcel, Integra Dermal Regeneration Template |
| Seapearl East, INC | $153.18 | 2023-2024 | |
| Medtronic Vascular, INC. | $117.69 | 2019 | |
| Horizon Therapeutics Plc | $116.15 | 2021 | |
| Kerecis Limited | $82.23 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Musculoskeletal Transplant Foundation INC. | $73.69 | 2024-2025 | |
| Tela Bio, INC. | $43.45 | 2024 | Ovitex 2s |
| Acera Surgical, INC. | $33.59 | 2024 | Restrata Wound Matrix |
| Biotronik Nro, INC. | $28.86 | 2023 | Biotronik |
| Medtronic, INC. | $28.80 | 2023 | Intellis Adaptivestim |
| Mentor Worldwide LLC | $22.81 | 2024 | Artoura Breast Tissue Expander |
| Smith+Nephew, INC. | $20.68 | 2024 | Pico 7 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Checkpoint Surgical, INC | $20.47 | 2025 | Checkpoint Stimulators |
| Davol INC. | $16.97 | 2025 | Phasix Mesh |
| Motiva USA, LLC | $16.06 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $14.81 | 2025 | |
| Depuy Synthes Sales INC. | $14.00 | 2023 | Matrixcombo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Yazid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.